All through the bird literature and feature films, there is much ado about dedicated emperor penguin males fasting for 115 days while they do all the incubation of the single egg. Sometimes, they may not fast for so long. Based on a winter visit to Cape Washington, we obtained evidence that some birds may feed before the egg is laid, and if they do, and some are males, then their fast is much less than 115 days. The consequence of a shorter fast for the male is a better chance of completing the 65 day incubation fast and success in fledging the chick. For those in northern colonies that may migrate south, there will be closer access to open water, but there will be the need to dive in the dark.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1242/jeb.170795 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Describing the landscape of nutrition- and diet-related randomized controlled trials: meta-research study of protocols published between 2012 and 2022.
Am J Clin Nutr
January 2025
UK EQUATOR Centre, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Electronic address:
Background: Publishing protocols promotes transparency and reproducibility. The scope and methods of protocols for nutrition- and diet-related randomized controlled trials (RCTs) have not been investigated yet.
Objective: Map the landscape of nutrition- and diet-related interventions research.
HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique.
Pathogens
January 2025
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC 20005, USA.
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021-February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition.
View Article and Find Full Text PDFStreamlining the Journey of Research Into Clinical Practice: Making Your Patients and Practice Flourish Evaluation and Treatment of Pyogenic Spondylodiscitis of the Spine: AO Spine Knowledge Forum Trauma and Infection.
Global Spine J
January 2025
Department of Orthopaedic Surgery, Rothman Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Study Design: Literature Review with clinical recommendations.
Objective: To highlight impactful studies on pyogenic spondylodiscitis (PS), identified by the AO Spine Knowledge Forum Trauma and Infection, with recommendations for their integration into clinical practice.
Methods: Five influential studies on PS that have the potential to shape current practice in spinal infections were selected and reviewed.
Genomics yields biological and phenotypic insights into bipolar disorder.
Nature
January 2025
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Bipolar disorder is a leading contributor to the global burden of disease. Despite high heritability (60-80%), the majority of the underlying genetic determinants remain unknown. We analysed data from participants of European, East Asian, African American and Latino ancestries (n = 158,036 cases with bipolar disorder, 2.
View Article and Find Full Text PDFPalovarotene in fibrodysplasia ossificans progressiva: review and perspective.
Expert Opin Pharmacother
January 2025
Amsterdam University Medical Center (Amsterdam UMC), location VU University Medical Center (VUMC), Amsterdam, Netherlands.
Introduction: Palovarotene is a retinoic acid receptor gamma agonist that was studied in phase-2 and phase-3 clinical trials for the inhibition of new heterotopic ossification (HO) in fibrodysplasia ossificans progressiva (FOP). Despite numerous setbacks and regulatory delays, palovarotene is now the first approved FOP treatment in the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!